There is also an arithmetic asymmetry inside the blend that separate vials make explicit and co-formulation hides: 5mg of a 1419.53 g/mol peptide is roughly 3.5 mol, while 5mg of a 4963.4 g/mol peptide is roughly 1.0 mol, so an equal-mass blend is close to a 3.5 to 1 molar ratio in favour of BPC-157
The breakthrough synthesis of BPC-157 arginate increased the 3% oral bioavailability of standard BPC-157 to greater than 90% in the arginate form
This is the more concentrated option, producing smaller injection volumes for any given dose
Finally, for teams looking for newer research items suggesting strong interest across experimental communities, take a look at SLUPP332 pills
Maintenance Phase: Once optimal B12 levels are achieved, the frequency of injections can be reduced
References Hsieh MJ, Liu HT, Wang CN, et al